A Phase 3 interventional study of Beclometasone/Formoterol/Glycopyrrolate and Beclometasone/Formoterol in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in Hungary. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. Beclomethasone · Pulmonary Disease, Chronic Obstructive.
Among the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive, this one has the largest enrollment, is one of 3 that started in 2014, is one of 3 in phase 3, and was the 6th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →None of the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →
Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,368 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 24 across the 13 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 13 have an industry lead sponsor. The 7 most frequent:
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A.: 5 open now, 5 under way, none of them phase 3. Of 62 finished, 7 (11%) have results posted.
Among the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., this one is the 7th largest by enrollment of the 59 interventional ones that give a count, is one of 8 that started in 2014, is one of 16 in phase 3, and was the 21st registered.
Chiesi Farmaceutici S.p.A.’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Chiesi Farmaceutici S.p.A.’s 68 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
Randomized,double-blind,multicenter,multinational,parallel-group,Phase III study to demonstrate the superiority of the triple fixed combination of beclometasone + formoterol + glycopyrrolate (BDP/FF/GB) administered via pressurised metered dose inhaler (pMDI) over the equivalent dose of Foster® (beclometasone dipropionate (BDP) / formoterol fumarate (FF), in patients diagnosed with chronic obstructive pulmonary disease (COPD) after 52 weeks of treatment.
This 52-week randomised 2 parallel groups study evaluated the superiority of fixed triple therapy with Inhaled Corticosteroid (ICS) / Long-Acting β2-Agonist (LABA) / Long-Acting Muscarinic Antagonist (LAMA) compared with ICS/LABA in patients with severe to very severe diagnosed of COPD.
Patients' eligibility was checked during the screening visit including the review of medical history, spirometry assessments, routine labs, physical examination, 12-lead electrocardiogram (ECG), vital signs measurement, prior to entering a 2-week open-label run-in period with BDP/FF to establish a baseline.
After the run-in period, eligible patients were randomised, to either fixed triple therapy BDP/FF/GB or BDP/FF treatment group. During the 52-week treatment period, patients who completed the study did have 5 subsequent visits post randomisation scheduled respectively after 4, 12, 26, 40, and 52 weeks of treatment. During these visits, pre-dose and post-dose spirometry, 12-lead ECG, vital signs, and dyspnoea assessments were performed. Rescue medication use, compliance with the treatment, and EXACT-PRO questionnaire [EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO)] were recorded daily (via an electronic diary) during the run-in and randomised treatment periods.
For pharmacovigilance purposes, adverse events (AE) were recorded from the time of patient informed consent signature until subject's study participation ended (Week 52 or early discontinuation).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CHF 5993 pMDI 100/6/12.5 µg 2 inhalations bid
Drug: Beclometasone/Formoterol/Glycopyrrolate
Foster® 100/6 µg 2 inhalations bid
Drug: Beclometasone/Formoterol
Drug pages: Beclomethasone · Formoterol · Glycopyrrolate
Active drug tested
Also known as: BDP/FF/GB or CHF 5993 pMDI 100/6/12.5 µg
Drug pages: Beclomethasone · Formoterol
Active comparator
Also known as: Foster® or CHF 1535 pMDI 100/6 µg
1_Change From Baseline in Pre-dose Morning Forced Expiratory Volume in the 1st Second (FEV1) -- at Week 26
Changes from baseline in pre-dose morning FEV1 to visit at Week 26. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
Time frame: Baseline (Week 0), Week 26.
2_Change From Baseline in 2-hour Post-dose FEV1 -- at Week 26
Change from baseline in 2-hour post-dose FEV1, at Week 26. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
Time frame: Baseline (Week 0) to 2-hour post-dose at Week 26.
3_Transition Dyspnoea Index (TDI) Focal Score -- at Week 26
Transition Dyspnoea Index (TDI) focal score is a symptom-based variable tool, used to assess breathlessness and the impact of intervention. BDI/TDI is a clinical rating method based on a validated tool that measures the impact of dyspnoea based on 3 domains: functional impairment, magnitude of task, and magnitude of effort. BDI focal score is the baseline value from which TDI focal score is assessed. BDI scores range from 0 (very severe impairment) to 4 (no impairment) for each domain with the baseline focal score consisting of the sum of each domain (i.e. from 0 to 12). Change from baseline in dyspnoea severity was measured using the TDI. TDI score ranges from -3 (major deterioration) to +3 (major improvement) for each domain, with the TDI focal score consisting of the sum of each domain (i.e. from -9 to +9). A higher total score indicates improvement, while a lower or negative score indicates worsening symptoms. BDI=Baseline Dyspnoea Index TDI=Transition Dyspnoea Index
Time frame: Baseline (Week 0), Week 26.
4_Change From Baseline in Pre-dose Morning FEV1 -- at All the Other Clinic Visits
Change from baseline in pre-dose morning FEV1, at all the other clinic visits. Please note: results at visit Week 26, are presented as the primary outcome measure #1 for this study. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
Time frame: Baseline (Week 0), Week 4. 12, 40, 52.
5_Change From Baseline to the Average in Pre-dose Morning FEV1 -- Over the Treatment Period
Changes from baseline for the average in pre-dose morning FEV1 over the treatment period. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
Time frame: Baseline (Week 0), Week 4, 12, 26, 40, 52.
6_Number of Participants Defined as Responders Wrt. to FEV1 -- Change From Baseline in Pre-dose Morning FEV1 ≥100 mL -- at Week 26 and Week 52
Number of participants defined as responders wrt. to FEV1 -- at Week 26 and Week 52. FEV1 response was defined as a change from baseline in pre-dose morning FEV1 of ≥100 mL. If the change from baseline was \<100 mL, the patient was classified as a non-responder in terms of FEV1. Subjects with missing pre-dose morning FEV1 value at the pre-specified tested time points were also classified as non-responders. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
Time frame: Baseline (Week 0), Week 26, Week 52.
7_Change From Baseline in 2-hour Post-dose of FEV1 -- at All the Other Clinic Visits
Change from baseline in 2-hour post-dose of FEV1, at all the other clinic visits. Please note: a) results at visit Week 26, are presented as the primary outcome measure #2 for this study; b) for Week 0, the measurement shown in the results table below was made 2 h after the baseline measurement i.e. pre-treatment at study baseline. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
Time frame: Baseline (Week 0), Week 4, 12, 40, 52.
8_Change From Pre-dose to 2-hour Post-dose FEV1 -- at All Study Visits
Change from pre-dose to 2-hour post-dose value of FEV1, at study visits on Week 4, 12, 26, 40, and 52. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
Time frame: Week 4, 12, 26, 40, 52.
9_Transition Dyspnoea Index (TDI) Focal Score -- at All Study Visits
TDI focal score is a symptom-based tool, used to assess breathlessness and the impact of intervention. BDI/TDI is a clinical rating method based on a validated tool that measures the impact of dyspnoea on 3 domains: functional impairment, magnitude of task, and magnitude of effort. TDI tool and its scoring system are defined in the outcome measure #3 of this PRS study entry. Please note: Results at Week 26, are presented as the primary outcome measure #3 for this PRS study entry. BDI=Baseline Dyspnoea Index TDI=Transition Dyspnoea Index
Time frame: Baseline (Week 0), Week 4, 12, 40, 52.
10_Number of Participants With Transition Dyspnoea Index (TDI) Response (Focal Score ≥1) -- at Week 26 and Week 52
Number of participants with transition dyspnoea index (TDI) response (focal score ≥1) -- at Week 26 and Week 52. TDI tool and its scoring system are defined in the outcome measure #3 of this PRS study entry. TDI response was defined as a TDI focal score of ≥1. If the TDI focal score was \<1, the patient was classified as a non-responder in terms of TDI. Patients with missing TDI focal score at the pre-specified tested time points were also classified as non-responders.
Time frame: Week 26, Week 52.
11a_Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) -- at All Study Visits: Total Score
Change from baseline in Saint George's respiratory questionnaire (SGRQ) Total score. SGRQ is a 76-item questionnaire developed to measure health in chronic airflow limitation. SGRQ consists of scores from three component that are used to calculate the total score: Symptoms, Activity, and Impacts on daily life. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, and Week 4, 12, 26, 40, 52). The Total score range is from 0 to 100 (0=Best, 100=Worst); lower scores correspond to better health. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, 4, 12, 26, 40, 52).
Time frame: Baseline (Week 0), Week 4, 12, 26, 40, 52.
11b_Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) -- at All Study Visits: Symptoms Score
Change from baseline in Saint George's respiratory questionnaire (SGRQ) -- Symptoms Score. SGRQ is a questionnaire developed to measure health in chronic airflow limitation. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, 4, 12, 26, 40, 52). Result show the Saint George's Respiratory Questionnaire (SGRQ) as change from baseline for the domain Symptoms. The Symptoms score is calculated on a scale of 0 to 100. A score of 0 indicates no impairment (best health); a score of 100 indicates the worst possible health status.
Time frame: Baseline (Week 0), Week 4, 12, 26, 40, 52.
11c_Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) -- at All Study Visits: Impacts Score
Saint George's respiratory questionnaire (SGRQ) -- Impacts Score. SGRQ is a questionnaire developed to measure health in chronic airflow limitation. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, 4, 12, 26, 40, 52). Result show the Saint George's Respiratory Questionnaire (SGRQ) as change from baseline for the domain Impacts. The Impact score is calculated on a scale of 0 to 100. A score of 0 indicates no impairment (best health); a score of 100 indicates the worst possible health status.
Time frame: Baseline (Week 0), Week 4, 12, 26, 40, 52.
11d_Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) -- at All Study Visits: Activity Score
Saint George's respiratory questionnaire (SGRQ) -- Activity score. SGRQ is a questionnaire developed to measure health in chronic airflow limitation. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, 4, 12, 26, 40, 52). Result show the Saint George's Respiratory Questionnaire (SGRQ) as change from baseline for the domain Activity. The Activity score is calculated on a scale of 0 to 100. A score of 0 indicates no impairment (best health); a score of 100 indicates the worst possible health status.
Time frame: Baseline (Week 0), Week 4, 12, 26, 40, 52.
12_Number of Participants With Saint George's Respiratory Questionnaire (SGRQ) Response (Change From Baseline in Total Score ≤-4) -- at Week 26 and Week 52
Number of participants with Saint George's Respiratory Questionnaire (SGRQ) response, defined as a change from baseline in SGRQ total score ≤ -4, at Week 26 and Week 52. If the change from baseline was \> -4, the patient was assessed as a non-responder in terms of SGRQ. Patients with missing change from baseline at the pre-specified tested time points were also classified as non-responders. Results shown represent the number of responder participants in terms of SGRQ, for the comparison of CHF 5993 pMDI versus CHF 1535 pMDI.
Time frame: Baseline (Week 0), Week 26, Week 52.
13a_Change From Baseline for Percentage of Days Without Intake of Rescue Medication -- Over Entire Treatment Period (52 Weeks of Treatment)
Days WITHOUT intake of rescue medication. Change from baseline to each inter-visit period and for the entire treatment period (Week 1-52) in the percentage of days without intake of rescue medication.
Time frame: Baseline (Week 0) to Week 4, 12, 26, 40, 52.
13b_Change From Baseline for the Average Use of Rescue Medication -- Over Entire Treatment Period (52 Weeks of Treatment)
Average use of rescue medication, over the entire treatment period (52 Weeks of treatment). Change from baseline to each inter-visit period and for the entire treatment period (Week 1-52) in the average use of rescue medication (number of puffs/day).
Time frame: Baseline (Week 0) to Week 4, 12, 26, 40, 52.
14_Rate of Moderate and Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Rate -- Over Entire Treatment Period (52 Weeks of Treatment)
Rate of moderate AND severe COPD exacerbations over the entire treatment period of treatment (52 weeks). COPD=Chronic obstructive pulmonary disease
Time frame: Baseline (Week 0) to Week 52 (entire treatment period).
15_First Occurrence of All Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
First occurrence of at least 1 moderate OR severe COPD exacerbation. First occurrence was analysed by Cox regression as time to first exacerbation and reported as hazard ratio. COPD=Chronic obstructive pulmonary disease
Time frame: Baseline (Week 0), Week 52.
| Milestone | CHF 5993 pMDI -- Beclometasone/Formoterol/Glycopyrrolate | Foster® pMDI -- Beclometasone/Formoterol |
|---|---|---|
| Started | 687 | 681 |
| Completed | 602 | 579 |
| Not completed | 85 | 102 |
| Withdrew: Adverse event, serious fatal | 13 | 15 |
| Withdrew: Withdrawal by subject | 45 | 54 |
| Withdrew: Adverse event | 20 | 17 |
| Withdrew: Lost to follow-up | 2 | 5 |
| Withdrew: Lack of efficacy | 3 | 6 |
| Withdrew: Protocol violation | 2 | 3 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Moved to another state; could not attend study visits. | 0 | 1 |
Changes from baseline in pre-dose morning FEV1 to visit at Week 26. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
| litre | CHF 5993 pMDI | CHF 1535 pMDI Foster® |
|---|---|---|
| 1_Change From Baseline in Pre-dose Morning Forced Expiratory Volume in the 1st Second (FEV1) -- at Week 26 | 0.082 (0.062 to 0.102) | 0.001 (-0.019 to 0.021) |
Change from baseline in 2-hour post-dose FEV1, at Week 26. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
| litre | CHF 5993 pMDI | CHF 1535 pMDI Foster® |
|---|---|---|
| 2_Change From Baseline in 2-hour Post-dose FEV1 -- at Week 26 | 0.261 (0.240 to 0.283) | 0.145 (0.123 to 0.166) |
Transition Dyspnoea Index (TDI) focal score is a symptom-based variable tool, used to assess breathlessness and the impact of intervention. BDI/TDI is a clinical rating method based on a validated tool that measures the impact of dyspnoea based on 3 domains: functional impairment, magnitude of task, and magnitude of effort. BDI focal score is the baseline value from which TDI focal score is assessed. BDI scores range from 0 (very severe impairment) to 4 (no impairment) for each domain with the baseline focal score consisting of the sum of each domain (i.e. from 0 to 12). Change from baseline in dyspnoea severity was measured using the TDI. TDI score ranges from -3 (major deterioration) to +3 (major improvement) for each domain, with the TDI focal score consisting of the sum of each domain (i.e. from -9 to +9). A higher total score indicates improvement, while a lower or negative score indicates worsening symptoms. BDI=Baseline Dyspnoea Index TDI=Transition Dyspnoea Index
| score on a scale | CHF 5993 pMDI | CHF 1535 pMDI Foster® |
|---|---|---|
| 3_Transition Dyspnoea Index (TDI) Focal Score -- at Week 26 | 1.71 (1.50 to 1.92) | 1.50 (1.29 to 1.71) |
Change from baseline in pre-dose morning FEV1, at all the other clinic visits. Please note: results at visit Week 26, are presented as the primary outcome measure #1 for this study. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
| litre | CHF 5993 pMDI | CHF 1535 pMDI Foster® |
|---|---|---|
| Week 4 | 0.093 (0.076 to 0.109) | 0.022 (0.005 to 0.039) |
| Week 12 | 0.078 (0.060 to 0.096) | 0.010 (-0.008 to 0.028) |
| Week 40 | 0.095 (0.073 to 0.116) | 0.018 (-0.004 to 0.040) |
| Week 52 | 0.071 (0.050 to 0.093) | 0.008 (-0.014 to 0.030) |
Changes from baseline for the average in pre-dose morning FEV1 over the treatment period. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
| litre | CHF 5993 pMDI | CHF 1535 pMDI Foster® |
|---|---|---|
| 5_Change From Baseline to the Average in Pre-dose Morning FEV1 -- Over the Treatment Period | 0.084 (0.067 to 0.100) | 0.012 (-0.005 to 0.029) |
Number of participants defined as responders wrt. to FEV1 -- at Week 26 and Week 52. FEV1 response was defined as a change from baseline in pre-dose morning FEV1 of ≥100 mL. If the change from baseline was \<100 mL, the patient was classified as a non-responder in terms of FEV1. Subjects with missing pre-dose morning FEV1 value at the pre-specified tested time points were also classified as non-responders. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
| Participants | CHF 5993 pMDI | CHF 1535 pMDI Foster® |
|---|---|---|
| Week 26 | 287 | 165 |
| Week 52 | 259 | 158 |
Change from baseline in 2-hour post-dose of FEV1, at all the other clinic visits. Please note: a) results at visit Week 26, are presented as the primary outcome measure #2 for this study; b) for Week 0, the measurement shown in the results table below was made 2 h after the baseline measurement i.e. pre-treatment at study baseline. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
| litre | CHF 5993 pMDI | CHF 1535 pMDI Foster® |
|---|---|---|
| Week 0 (measurement made 2 h after baseline) | 0.215 (0.203 to 0.228) | 0.138 (0.126 to 0.150) |
| Week 4 | 0.268 (0.250 to 0.286) | 0.153 (0.135 to 0.171) |
| Week 12 | 0.261 (0.241 to 0.281) | 0.146 (0.125 to 0.166) |
| Week 40 | 0.253 (0.230 to 0.275) | 0.150 (0.127 to 0.174) |
| Week 52 | 0.249 (0.226 to 0.273) | 0.146 (0.122 to 0.170) |
Change from pre-dose to 2-hour post-dose value of FEV1, at study visits on Week 4, 12, 26, 40, and 52. FEV1=Forced expiratory volume in the 1st second. It is the volume of air that can be forced out in one second after taking a deep breath.
| liter | CHF 5993 pMDI | CHF 1535 pMDI Foster® |
|---|---|---|
| Week 4 | 0.177 (0.165 to 0.189) | 0.130 (0.118 to 0.143) |
| Week 12 | 0.183 (0.171 to 0.194) | 0.138 (0.126 to 0.149) |
| Week 26 | 0.180 (0.169 to 0.192) | 0.149 (0.138 to 0.161) |
| Week 40 | 0.159 (0.147 to 0.171) | 0.138 (0.125 to 0.150) |
| Week 52 | 0.180 (0.167 to 0.193) | 0.146 (0.133 to 0.159) |
TDI focal score is a symptom-based tool, used to assess breathlessness and the impact of intervention. BDI/TDI is a clinical rating method based on a validated tool that measures the impact of dyspnoea on 3 domains: functional impairment, magnitude of task, and magnitude of effort. TDI tool and its scoring system are defined in the outcome measure #3 of this PRS study entry. Please note: Results at Week 26, are presented as the primary outcome measure #3 for this PRS study entry. BDI=Baseline Dyspnoea Index TDI=Transition Dyspnoea Index
| score on a scale | CHF 5993 pMDI | CHF 1535 pMDI Foster® |
|---|---|---|
| Week 4 | 1.54 (1.35 to 1.72) | 1.12 (0.94 to 1.31) |
| Week 12 | 1.77 (1.58 to 1.97) | 1.39 (1.19 to 1.58) |
| Week 40 | 1.80 (1.58 to 2.01) | 1.65 (1.43 to 1.86) |
| Week 52 | 2.03 (1.81 to 2.25) | 1.81 (1.59 to 2.04) |
Number of participants with transition dyspnoea index (TDI) response (focal score ≥1) -- at Week 26 and Week 52. TDI tool and its scoring system are defined in the outcome measure #3 of this PRS study entry. TDI response was defined as a TDI focal score of ≥1. If the TDI focal score was \<1, the patient was classified as a non-responder in terms of TDI. Patients with missing TDI focal score at the pre-specified tested time points were also classified as non-responders.
| Participants | CHF 5993 pMDI | CHF 1535 pMDI Foster® |
|---|---|---|
| Week 26 | 394 | 352 |
| Week 52 | 370 | 354 |
Change from baseline in Saint George's respiratory questionnaire (SGRQ) Total score. SGRQ is a 76-item questionnaire developed to measure health in chronic airflow limitation. SGRQ consists of scores from three component that are used to calculate the total score: Symptoms, Activity, and Impacts on daily life. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, and Week 4, 12, 26, 40, 52). The Total score range is from 0 to 100 (0=Best, 100=Worst); lower scores correspond to better health. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, 4, 12, 26, 40, 52).
| score on a scale | CHF 5993 pMDI | CHF 1535 pMDI Foster® |
|---|---|---|
| Week 4 | -3.66 (-4.41 to -2.91) | -2.19 (-2.96 to -1.43) |
| Week 12 | -4.70 (-5.58 to -3.81) | -2.66 (-3.55 to -1.77) |
| Week 26 | -4.76 (-5.69 to -3.83) | -3.43 (-4.38 to -2.47) |
| Week 40 | -5.48 (-6.49 to -4.47) | -4.08 (-5.11 to -3.05) |
| Week 52 | -5.12 (-6.18 to -4.06) | -3.43 (-4.51 to -2.35) |
Change from baseline in Saint George's respiratory questionnaire (SGRQ) -- Symptoms Score. SGRQ is a questionnaire developed to measure health in chronic airflow limitation. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, 4, 12, 26, 40, 52). Result show the Saint George's Respiratory Questionnaire (SGRQ) as change from baseline for the domain Symptoms. The Symptoms score is calculated on a scale of 0 to 100. A score of 0 indicates no impairment (best health); a score of 100 indicates the worst possible health status.
| score on a scale | CHF 5993 pMDI | CHF 1535 pMDI Foster® |
|---|---|---|
| Week 4 | -5.02 (-6.10 to -3.95) | -3.83 (-4.92 to -2.75) |
| Week 12 | -5.09 (-6.29 to -3.89) | -4.56 (-5.77 to -3.34) |
| Week 26 | -6.80 (-8.06 to -5.53) | -5.17 (-6.46 to -3.88) |
| Week 40 | -8.35 (-9.73 to -6.96) | -7.12 (-8.53 to -5.71) |
| Week 52 | -8.22 (-9.67 to -6.77) | -7.26 (-8.74 to -5.78) |
Saint George's respiratory questionnaire (SGRQ) -- Impacts Score. SGRQ is a questionnaire developed to measure health in chronic airflow limitation. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, 4, 12, 26, 40, 52). Result show the Saint George's Respiratory Questionnaire (SGRQ) as change from baseline for the domain Impacts. The Impact score is calculated on a scale of 0 to 100. A score of 0 indicates no impairment (best health); a score of 100 indicates the worst possible health status.
| score on a scale | CHF 5993 pMDI | CHF 1535 pMDI Foster® |
|---|---|---|
| Week 4 | -3.44 (-4.34 to -2.54) | -2.29 (-3.20 to -1.38) |
| Week 12 | -4.65 (-5.69 to -3.62) | -2.72 (-3.76 to -1.68) |
| Week 26 | -4.88 (-5.96 to -3.80) | -3.50 (-4.60 to -2.39) |
| Week 40 | -5.33 (-6.45 to -4.20) | -3.75 (-4.89 to -2.60) |
| Week 52 | -4.68 (-5.85 to -3.51) | -2.59 (-3.79 to -1.40) |
Saint George's respiratory questionnaire (SGRQ) -- Activity score. SGRQ is a questionnaire developed to measure health in chronic airflow limitation. SGRQ questionnaire was completed by the patient at all study visits (Week 0 baseline, 4, 12, 26, 40, 52). Result show the Saint George's Respiratory Questionnaire (SGRQ) as change from baseline for the domain Activity. The Activity score is calculated on a scale of 0 to 100. A score of 0 indicates no impairment (best health); a score of 100 indicates the worst possible health status.
| score on a scale | CHF 5993 pMDI | CHF 1535 pMDI Foster® |
|---|---|---|
| Week 4 | -2.69 (-3.65 to -1.73) | -1.21 (-2.18 to -0.24) |
| Week 12 | -3.93 (-5.03 to -2.83) | -1.35 (-2.46 to -0.24) |
| Week 26 | -3.88 (-5.01 to -2.75) | -2.17 (-3.33 to -1.02) |
| Week 40 | -4.35 (-5.54 to -3.15) | -2.74 (-3.96 to -1.51) |
| Week 52 | -4.26 (-5.49 to -3.02) | -2.95 (-4.21 to -1.68) |
Number of participants with Saint George's Respiratory Questionnaire (SGRQ) response, defined as a change from baseline in SGRQ total score ≤ -4, at Week 26 and Week 52. If the change from baseline was \> -4, the patient was assessed as a non-responder in terms of SGRQ. Patients with missing change from baseline at the pre-specified tested time points were also classified as non-responders. Results shown represent the number of responder participants in terms of SGRQ, for the comparison of CHF 5993 pMDI versus CHF 1535 pMDI.
| Participants | CHF 5993 pMDI | CHF 1535 pMDI Foster® |
|---|---|---|
| Week 26 | 321 | 246 |
| Week 52 | 297 | 244 |
Days WITHOUT intake of rescue medication. Change from baseline to each inter-visit period and for the entire treatment period (Week 1-52) in the percentage of days without intake of rescue medication.
| percentage of days | CHF 5993 pMDI | CHF 1535 pMDI Foster® |
|---|---|---|
| Week 1-4 | 6.67 (4.89 to 8.44) | 2.46 (0.67 to 4.25) |
| Week 5-12 | 6.23 (4.19 to 8.27) | 3.18 (1.12 to 5.24) |
| Week 13-26 | 5.49 (3.30 to 7.67) | 2.40 (0.19 to 4.60) |
| Week 27-40 | 4.39 (2.07 to 6.72) | 2.79 (0.43 to 5.15) |
| Week 41-52 | 3.82 (1.45 to 6.19) | 1.24 (-1.17 to 3.65) |
| Week 1-52 | 5.01 (3.05 to 6.98) | 2.36 (0.37 to 4.35) |
Average use of rescue medication, over the entire treatment period (52 Weeks of treatment). Change from baseline to each inter-visit period and for the entire treatment period (Week 1-52) in the average use of rescue medication (number of puffs/day).
| puffs/day | CHF 5993 pMDI | CHF 1535 pMDI Foster® |
|---|---|---|
| Week 1-4 | -0.29 (-0.38 to -0.20) | -0.07 (-0.17 to 0.02) |
| Week 5-12 | -0.25 (-0.36 to -0.14) | -0.06 (-0.17 to 0.05) |
| Week 13-26 | -0.21 (-0.32 to -0.09) | -0.02 (-0.14 to 0.10) |
| Week 27-40 | -0.09 (-0.22 to 0.04) | 0.02 (-0.11 to 0.15) |
| Week 41-52 | -0.04 (-0.17 to 0.09) | 0.07 (-0.07 to 0.21) |
| Week 1-52 | -0.15 (-0.26 to -0.04) | 0.00 (-0.11 to 0.12) |
Rate of moderate AND severe COPD exacerbations over the entire treatment period of treatment (52 weeks). COPD=Chronic obstructive pulmonary disease
| events per patient per year | CHF 5993 pMDI | CHF 1535 pMDI Foster® |
|---|---|---|
| 14_Rate of Moderate and Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Rate -- Over Entire Treatment Period (52 Weeks of Treatment) | 0.410 (0.358 to 0.469) | 0.530 (0.468 to 0.600) |
First occurrence of at least 1 moderate OR severe COPD exacerbation. First occurrence was analysed by Cox regression as time to first exacerbation and reported as hazard ratio. COPD=Chronic obstructive pulmonary disease
| number of first occurrences | CHF 5993 pMDI | CHF 1535 pMDI Foster® |
|---|---|---|
| 15_First Occurrence of All Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation | 214 | 240 |
Collected over Adverse events (AE) were reported from the time of patient informed consent signature until subject's study participation ended (Week 52 or early withdrawal).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Beclometasone/Formoterol/Glycopyrrolate | 15/687 (2.2%) | 106/687 (15.4%) | 181/687 (26.3%) |
| Beclometasone/Formoterol | 16/680 (2.4%) | 123/680 (18.1%) | 203/680 (29.9%) |
| Event | Beclometasone/Formoterol/Glycopyrrolate | Beclometasone/Formoterol |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 66/687 | 75/680 |
| PneumoniaInfections and infestations | 14/687 | 6/680 |
| Myocardial ischaemiaCardiac disorders | 0/687 | 4/680 |
| Cardiac failureCardiac disorders | 4/687 | 3/680 |
| Acute myocardial infarctionCardiac disorders | 0/687 | 3/680 |
| Myocardial infarctionCardiac disorders | 1/687 | 3/680 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/687 | 1/680 |
| Atrial fibrillationCardiac disorders | 3/687 | 1/680 |
| Lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/687 | 2/680 |
| Sudden deathGeneral disorders | 0/687 | 2/680 |
| Event | Beclometasone/Formoterol/Glycopyrrolate | Beclometasone/Formoterol |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 159/687 | 184/680 |
| NasopharyngitisInfections and infestations | 39/687 | 38/680 |
Safety population: all randomised patients who received at least one dose of the study treatment. One patient in the CHF 1535 pMDI group did not use the study medication kit provided at V2 and withdrew consent a few days after the visit.
| Age, Continuous(years) | CHF 5993 pMDI Beclometasone/Formoterol/Glycopyrrolate | CHF 1535 pMDI Foster® Beclometasone/Formoterol | Total |
|---|---|---|---|
| Mean | 63.3 ± 7.9 | 63.8 ± 8.2 | 63.6 ± 8.1 |
| Age, Customized(Participants) | CHF 5993 pMDI Beclometasone/Formoterol/Glycopyrrolate | CHF 1535 pMDI Foster® Beclometasone/Formoterol | Total |
|---|---|---|---|
| Adults (<65 years) | 391 | 347 | 738 |
| Adults (≥65 years to 74 years) | 237 | 266 | 503 |
| Adults (≥75) | 59 | 67 | 126 |
| Sex: Female, Male(Participants) | CHF 5993 pMDI Beclometasone/Formoterol/Glycopyrrolate | CHF 1535 pMDI Foster® Beclometasone/Formoterol | Total |
|---|---|---|---|
| Female | 178 | 153 | 331 |
| Male | 509 | 527 | 1036 |
| Race/Ethnicity, Customized(Participants) | CHF 5993 pMDI Beclometasone/Formoterol/Glycopyrrolate | CHF 1535 pMDI Foster® Beclometasone/Formoterol | Total |
|---|---|---|---|
| Other | 3 | 1 | 4 |
| White | 684 | 679 | 1363 |
| Region of Enrollment(participants) | CHF 5993 pMDI Beclometasone/Formoterol/Glycopyrrolate | CHF 1535 pMDI Foster® Beclometasone/Formoterol | Total |
|---|---|---|---|
| Argentina | 28 | 25 | 53 |
| Belgium | 4 | 3 | 7 |
| Bulgaria | 46 | 46 | 92 |
| Czechia | 104 | 104 | 208 |
| Germany | 31 | 32 | 63 |
| Hungary | 52 | 51 | 103 |
| Italy | 11 | 12 | 23 |
| Mexico | 3 | 1 | 4 |
| Poland | 57 | 56 | 113 |
| Romania | 53 | 52 | 105 |
| Russia | 160 | 159 | 319 |
| Slovakia | 15 | 18 | 33 |
| Ukraine | 113 | 111 | 224 |
| United Kingdom | 10 | 10 | 20 |
| Time since first COPD diagnosis (years(years) | CHF 5993 pMDI Beclometasone/Formoterol/Glycopyrrolate | CHF 1535 pMDI Foster® Beclometasone/Formoterol | Total |
|---|---|---|---|
| Mean | 7.71 ± 5.75 | 7.67 ± 5.98 | 7.69 ± 5.87 |
| Main COPD phenotype(Participants) | CHF 5993 pMDI Beclometasone/Formoterol/Glycopyrrolate | CHF 1535 pMDI Foster® Beclometasone/Formoterol | Total |
|---|---|---|---|
| Chronic bronchitis only | 336 | 332 | 668 |
| Emphysema only | 220 | 197 | 417 |
| Chronic bronchitis and emphysema | 114 | 131 | 245 |
| Unknown | 17 | 20 | 37 |
| Number of COPD exacerbations in the previous year(Participants) | CHF 5993 pMDI Beclometasone/Formoterol/Glycopyrrolate | CHF 1535 pMDI Foster® Beclometasone/Formoterol | Total |
|---|---|---|---|
| 1 Exacerbation | 551 | 546 | 1097 |
| 2 Exacerbations | 116 | 114 | 230 |
| 3 Exacerbations | 17 | 17 | 34 |
| >3 Exacerbations | 3 | 3 | 6 |
4 further baseline measures are reported on the registry.
Plan to share: Yes — Chiesi clinical data sharing scope, process and data access criteria is available on the Chiesi Group website.
Ran from Mar 2014 to primary completion in Jan 2016, 21 months.
Results were first posted in Jun 2026, 10 years 4 months after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 21 months is close to that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Beclomethasone · Formoterol · Glycopyrrolate
Pulmonary Disease, Chronic Obstructive →